A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. RBendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age with Previously Untreated Mantle Cell Lymphoma

Version date: 03/01/2013

Checklist For Submission Of Radiation Oncology Quality Assurance Materials

Patient:	Protocol:	S1106	Registration#	
Send material c/o:	Treating Radiation Oncologist:			
Quality Assurance Review Center	Name:			
640 George Washington Hgwy	Address:			
Building A, Suite 201				
Lincoln, RI 02865				
	E-mail:			
Date Radiation Began:				
<u> </u>				
*A TBI Benchmark must be completed	d and submitted to	QARC pr	ior to participation on this study.	
-				
The following TBI Review materials m	ust be submitted	upon com	pletion of radiotherapy:	
DATE				
<u>DATE</u> <u>SUBMITTED</u>				
QARC TBI Summar	ry form (available at	www.qarc	.org)	
RT Daily Treatment	Record including p	rescription	, daily and cumulative doses	
	0 1	•		

Please enclose a copy of this Checklist together with the RT materials you submit. All materials must be labeled with the assigned protocol and registration number.

Please contact SWOG CRA by calling Tel: (401) 753-7600 or email at swog@qarc.org for clarification as necessary. Thank you for your ongoing co-operation.